Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

1.100 -0.020 (-1.79%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain
Via TheNewswire.com
News headline image
BioRestorative Announces Share Repurchase Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based 
Via PressReach
News headline image
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based 
Via PressReach
News headline image
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based 
Via PressReach
News headline image
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based 
Via PressReach
News headline image
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
Via TheNewswire.com
News headline image
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga 
Via TheNewswire.com
News headline image
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
Via ACCESSWIRE
News headline image
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
Via ACCESSWIRE
News headline image
Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”
Via ACCESSWIRE
News headline image
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Via ACCESSWIRE
News headline image
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
Via ACCESSWIRE
News headline image
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion
Via ACCESSWIRE
News headline image
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
Via ACCESSWIRE
News headline image
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
Via ACCESSWIRE
News headline image
BioResorative CEO is Featured in An Interview With SmallCaps Daily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It
Via ACCESSWIRE
News headline image
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
Via ACCESSWIRE
BioRestorative Therapies, Inc. (NASDAQ: BRTX) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
By Julian Richard, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Receives Notice of Third US Patent Related to ThermoStem IP
Via Investor Brand Network
Topics Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
By Julian Richard, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program
Via Investor Brand Network
Topics Intellectual Property
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
By Julian Richard, Benzinga 
Via TheNewswire.com
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
News headline image
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
From BioRestorative Therapies, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.